Stryker Corp
SYK
275.40
-2.80
-1.01%
Stryker Corp
US · SYK
#199 by market cap
Listed 1970
275.40
-2.80
-1.01%
Live - 5344 symbols - heartbeat 7s ago
· 2026-10-08 08:27
Pre-market
275.57
+0.06%
After-hours
276.30
+0.33%
Overnight
275.65
+0.09%
- Market cap
- 105.64B
- P/E (TTM)i
- 28.54
- P/Bi
- 4.40
- EPSi
- 8.40
- Div yieldi
- 1.26%
- 52W posi
- 8%
Reader sentiment
Are you bullish or bearish on SYK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.14, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.16% YoY
Margins
- Gross margin
- 63.96%
- Operating margin
- 20.14%
- Net margin
- 12.92%
Key ratios & quality
- Enterprise valuei
- 117.40B
- PEG ratioi
- 2.54
- Altman Z-Scorei
- 4.14
PEG uses trailing P/E against the 3-year net income growth rate (11.24%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.60B | 14.88B | 14.35B | 17.11B | 18.45B | 20.50B | 22.60B | 25.12B |
| Gross profit | 8.94B | 9.70B | 9.06B | 10.97B | 11.58B | 13.06B | 14.44B | 16.07B |
| Selling & admin expenses | 5.10B | 5.36B | 5.36B | 6.43B | 6.39B | 7.11B | 7.69B | 8.65B |
| Research & development | 862.00M | 971.00M | 984.00M | 1.24B | 1.45B | 1.39B | 1.47B | 1.62B |
| Operating profit | 2.56B | 2.91B | 2.24B | 2.69B | 3.11B | 3.92B | 4.67B | 5.06B |
| Pretax profit | 2.36B | 2.56B | 1.95B | 2.28B | 2.68B | 3.67B | 3.49B | 4.51B |
| Tax | -1.20B | 479.00M | 355.00M | 287.00M | 325.00M | 508.00M | 499.00M | 1.27B |
| Net profit | 3.55B | 2.08B | 1.60B | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
| Basic EPS | 10 | 6 | 4 | 5 | 6 | 8 | 8 | 8 |
| Diluted EPS | 9.34 | 5.48 | 4.20 | 5.21 | 6.17 | 8.25 | 7.76 | 8.40 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 5.87B | 6.02B | 6.06B | 7.17B | 6.02B | 6.59B |
| Gross profit | 3.74B | 3.84B | 3.85B | 4.63B | 3.81B | 4.50B |
| Selling & admin expenses | 2.30B | 2.08B | 2.05B | 2.23B | 2.28B | 2.23B |
| Research & development | 405.00M | 407.00M | 410.00M | 401.00M | 413.00M | 434.00M |
| Operating profit | 872.00M | 1.17B | 1.21B | 1.81B | 936.00M | 1.66B |
| Pretax profit | 764.00M | 1.02B | 1.03B | 1.71B | 850.00M | 1.56B |
| Tax | 110.00M | 132.00M | 170.00M | 856.00M | 105.00M | 288.00M |
| Net profit | 654.00M | 884.00M | 859.00M | 849.00M | 745.00M | 1.28B |
| Basic EPS | 2 | 2 | 2 | 2 | 2 | 3 |
| Diluted EPS | 1.69 | 2.29 | 2.22 | 2.20 | 1.93 | 3.30 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 9.73B | 11.06B | 9.71B | 10.02B | 10.28B | 12.52B | 14.85B | 14.76B |
| Cash & ST investments | 3.70B | 4.43B | 3.02B | 3.02B | 1.93B | 3.05B | 4.49B | 4.10B |
| Inventory | 2.96B | 2.98B | 3.49B | 3.31B | 4.00B | 4.84B | 4.77B | 5.31B |
| Total assets | 27.23B | 30.17B | 34.33B | 34.63B | 36.88B | 39.91B | 42.97B | 47.84B |
| Total current liabilities | 4.81B | 4.40B | 5.04B | 4.55B | 6.30B | 7.92B | 7.62B | 7.79B |
| Short-term debt | 1.37B | 859.00M | 761.00M | 7.00M | 1.19B | 2.09B | 1.41B | 1.00B |
| Long-term debt | 8.49B | 10.23B | 13.23B | 12.47B | 11.86B | 10.90B | 12.19B | 14.86B |
| Total liabilities | 15,499,000,000.00 | 17,360,000,000.00 | 21,246,000,000.00 | 19,754,000,000.00 | 20,268,000,000.00 | 21,319,000,000.00 | 22,337,000,000.00 | 25,424,000,000.00 |
| Total equity | 11.73B | 12.81B | 13.08B | 14.88B | 16.62B | 18.59B | 20.63B | 22.42B |
| Retained earnings | 10.77B | 11.75B | 12.46B | 13.48B | 14.77B | 16.77B | 18.53B | 20.47B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 13.02B | 13.00B | 13.71B | 14.76B | 13.34B | 14.42B |
| Cash & ST investments | 2.41B | 2.46B | 3.34B | 4.10B | 2.97B | 3.48B |
| Inventory | 5.11B | 5.29B | 5.37B | 5.31B | 5.42B | 5.52B |
| Total assets | 46.01B | 46.33B | 47.06B | 47.84B | 46.29B | 47.93B |
| Total current liabilities | 7.93B | 7.29B | 7.41B | 7.79B | 6.32B | 6.68B |
| Short-term debt | 2.40B | 1.75B | 1.75B | 1.00B | 499.00M | 750.00M |
| Long-term debt | 14.38B | 14.83B | 14.85B | 14.86B | 14.22B | 14.19B |
| Total liabilities | 25,076,000,000.00 | 25,140,000,000.00 | 25,272,000,000.00 | 25,424,000,000.00 | 23,312,000,000.00 | 23,942,000,000.00 |
| Total equity | 20.93B | 21.19B | 21.79B | 22.42B | 22.98B | 23.99B |
| Retained earnings | 18.86B | 19.42B | 19.96B | 20.47B | 20.88B | 21.82B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.61B | 2.19B | 3.28B | 3.26B | 2.62B | 3.71B | 4.24B | 5.04B |
| Depreciation & amortization | 723.00M | 778.00M | 812.00M | 990.00M | 998.00M | 1.03B | 1.05B | 1.19B |
| Free cash flow | 2.04B | 1.54B | 2.79B | 2.74B | 2.04B | 3.14B | 3.49B | 4.28B |
| Dividends paid | -703.00M | -778.00M | -863.00M | -950.00M | -1.05B | -1.14B | -1.22B | -1.28B |
| Stock buybacks / issuance | -300.00M | -307.00M | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 3.62B | 4.34B | 2.94B | 2.94B | 1.84B | 2.97B | 3.65B | 4.01B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 250.00M | 1.11B | 1.54B | 2.14B | 581.00M | 1.26B |
| Depreciation & amortization | 272.00M | 296.00M | 309.00M | 316.00M | 300.00M | 296.00M |
| Free cash flow | 127.00M | 928.00M | 1.35B | 1.88B | 415.00M | 1.06B |
| Dividends paid | -320.00M | -321.00M | -322.00M | -321.00M | -337.00M | -337.00M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 2.32B | 2.38B | 3.26B | 4.01B | 2.88B | 3.39B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 32.75 | 16.98 | 12.35 | 14.26 | 14.97 | 17.98 | 15.26 | 15.08 |
| ROA %i | 14.38 | 7.26 | 4.96 | 5.78 | 6.59 | 8.24 | 7.22 | 7.15 |
| ROIC %i | 18.33 | 9.16 | 6.27 | 7.33 | 8.27 | 10.33 | 9.09 | 10.16 |
| 5-year avg ROE %i | 16.82 | 19.05 | 18.15 | 17.36 | 18.26 | 15.31 | 14.97 | 15.51 |
| EBIT margin %i | 18.82 | 19.52 | 15.61 | 15.71 | 16.49 | 19.06 | 20.65 | 20.39 |
| FCF / sales %i | 14.98 | 10.36 | 19.44 | 16.00 | 11.04 | 15.30 | 15.43 | 17.05 |
| Current ratioi | 2.02 | 2.51 | 1.93 | 2.20 | 1.63 | 1.58 | 1.95 | 1.89 |
| Quick ratioi | 1.25 | 1.66 | 1.14 | 1.33 | 0.87 | 0.86 | 1.11 | 1.04 |
| Debt / assetsi | 36.21 | 36.76 | 40.75 | 36.03 | 35.38 | 32.56 | 31.64 | 33.15 |
| LT debt / equityi | 72.34 | 79.89 | 101.12 | 83.83 | 71.36 | 58.63 | 59.07 | 66.28 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | 8.44 |
| Revenue CAGR (3Y) %i | 11.00 | 9.54 | 4.87 | 7.95 | 7.42 | 12.62 | 9.72 | 10.83 |
| Net income CAGR (3Y) %i | 35.16 | 8.14 | 16.17 | -17.51 | 4.22 | 25.56 | 14.50 | 11.24 |
| FCF CAGR (3Y) %i | 42.05 | 2.67 | 42.66 | 10.34 | 9.71 | 3.97 | 8.39 | 28.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 14.26 | 14.25 | 14.04 | 15.08 | 15.20 | 16.51 |
| ROA %i | 6.69 | 6.83 | 6.48 | 7.15 | 7.23 | 7.91 |
| ROIC %i | 8.20 | 8.37 | 7.95 | 10.16 | 10.04 | 10.86 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 19.65 | 19.58 | 19.63 | 20.39 | 20.65 | 22.25 |
| FCF / sales %i | 15.41 | 16.89 | 16.71 | 17.05 | 18.09 | 18.20 |
| Current ratioi | 1.64 | 1.78 | 1.85 | 1.89 | 2.11 | 2.16 |
| Quick ratioi | 0.80 | 0.88 | 0.94 | 1.04 | 1.03 | 1.08 |
| Debt / assetsi | 36.48 | 35.79 | 35.27 | 33.15 | 31.81 | 31.17 |
| LT debt / equityi | 68.72 | 69.98 | 68.14 | 66.28 | 61.90 | 59.16 |
| Interest coveragei | -- | -- | -- | 8.44 | 8.44 | 9.58 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- MedSurg and Neurotechnology is the largest reported line at 55.02% of revenue, across 2 reported segments.
- Orthopaedics follows at 44.98%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
MedSurg and Neurotechnology55.02%
Orthopaedics44.98%
Quote time 2026-10-08 08:27:05 · For reference only, not investment advice and not tailored to your situation.